The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 2, 2010, Pages 126-140

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Spirito, Nicoletta ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antibiotic prophylaxis; Bowel preparation for surgery; Gynaecological surgery; Postoperative oral feeding; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIVITAMIN K; BETA LACTAM; CEFAZOLIN; CEFMETAZOLE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; DALTEPARIN; DOXYCYCLINE; ENOXAPARIN; FONDAPARINUX; GENTAMICIN; HEPARIN; IMIPENEM; LATAMOXEF; LOW MOLECULAR WEIGHT HEPARIN; METRONIDAZOLE; NEOMYCIN; NETILMICIN; PENICILLIN G; PIPERACILLIN; PLACEBO; TIGECYCLINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL SURGERY; ANAPHYLAXIS; ANESTHESIA INDUCTION; ANTICOAGULATION; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL SURGERY; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; ELECTIVE SURGERY; FEEDING; GRAM NEGATIVE BACTERIUM; GYNECOLOGIC CANCER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ILEUS; IN VITRO STUDY; INFECTION PREVENTION; INTESTINE PREPARATION; LENGTH OF STAY; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR SURGERY; MORBIDITY; NAUSEA; PATHOGENESIS; PENICILLIN ALLERGY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; REVIEW; RISK ASSESSMENT; SEPSIS; VENOUS THROMBOEMBOLISM; WOUND INFECTION;

ANTIBIOTIC PROPHYLAXIS; CARCINOMA; COLORECTAL SURGERY; CONSENSUS; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

EID: 73749086376     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.02.008     Document Type: Review

References (151)

1. Rickles F.R., and Edwards R.L. Activation of blood coagulation in cancer: Trousseau's Syndrome revisited. Blood 62 (1983) 14-31
2. Nand S. Hemostasis and cancer. Cancer J 6 (1993) 54-58
3. Gadducci A., Baicchi U., Marrai R., Del Bravo B., Fosella P.V., and Facchini V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 53 (1994) 352-356
4. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 31 (2005) 104-110
5. Elalamy I., Verdy E., Gerotziafas G., and Hatmi M. Pathogenesis of venous thromboembolic disease in cancer. Pathol Biol (Paris) 56 (2008) 184-194
6. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50 (2004) 187-196
7. Kakkar A.K., DeRuvo N., Chinswangwatanakul V., Tebbutt J., and Williamson R.C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346 (1995) 1004-1005
8. Semeraro N. Different expression of procoagulant activity in macrophages associated with experimental and human tumors. Haemostasis 18 (1988) 47-54
9. Falanga A., and Rickles F.R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25 (1999) 173-182
10. Lee A.Y. Cancer and thromboembolic disease: pathogenetic mechanisms. Cancer Treat Rev 28 (2002) 137-140
11. Rickles F.R., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
12. Sue-Ling H.M., Johnston D., McMahon M.J., Philips P.R., and Davies J.A. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1 (1986) 1173-1176
13. Lee A.Y., and Levine M.N. The thrombophilic state induced by therapeutic agents in cancer patients. Semin Thromb Hemost 25 (1999) 137-145
14. Hallahan D., Chen A.Y., Teng M., and Cmelak A.J. Drug-radiation interactions in tumor blood vessels. Oncology 13 (1999) 71-77
15. Khorana A.A., Liebman H.A., White R.H., Wun T., and Lyman G.H. The risk of venous thromboembolism in patients with cancer. American Society of Clinical Oncology, 2008 educational book, 44th annual meeting. May 30-June 3, Chicago, IL (2008) 240-248
16. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 338S-400S
17. Agnelli G., Bolis G., Capussotti L., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg 243 (2006) 89-95
18. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
19. Rogers II J.S., Murgo A.J., Fontana J.A., and Raich P.C. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6 (1988) 276-281
20. Bertomeu M.C., Gallo S., Lauri D., Levine M.N., Orr F.W., and Buchanan M.R. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 8 (1990) 511-518
21. Stähli B.E., Camici G.G., Steffel J., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99 (2006) 149-155
22. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
23. Verso M., and Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21 (2003) 3665-3675
24. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112 (1990) 423-428
25. Monreal M., Alastrue A., Rull M., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75 (1996) 251-253
26. Heaton D.C., Han D.Y., and Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 32 (2002) 84-88
27. Mismetti P., Mille D., Laporte S., et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 88 (2003) 67-73
28. Abdelkefi A., Ben Othman T., Kammoun L., et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 92 (2004) 654-661
29. Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005) 4057-4062
30. Young A.M., Begum G., Billingham L.J., et al. WARP-a multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol 23 16 suppl. (2005) [abstract LBA8004]
31. Ruud E., Holmstrom H., De Lange C., Hogstad E.M., and Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies-a randomized, controlled study. Acta Paediatr 95 (2006) 1053-1059
32. Karthaus M., Kretzschmar A., Kroning H., et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17 (2006) 289-296
33. Akl E.A., Kamath G., Yosuico V., et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 112 (2008) 2483-2492
34. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
35. Thodiyil P.A., and Kakkar A.K. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87 (2002) 1076-1077
36. Svendsen E., and Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 42 (1989) 805-809
37. Chew H.K., Wun T., Harvey D., Zhou H., and White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006) 458-464
38. Rodriguez A.O., Wun T., Chew H., Zhou H., Harvey D., and White R.H. Venous thromboembolism in ovarian cancer. Gynecol Oncol 105 (2007) 784-790
39. Einstein M.H., Pritts E.A., and Hartenbach E.M. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 105 (2007) 813-819
40. Oates-Whitehead R.M., D'Angelo A., and Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev 18 (2007) CD003679
41. von Tempelhoff G.F., and Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am 14 (2000) 1151-1169
42. Wille-Jørgensen P., Rasmussen M.S., Andersen B.R., and Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev 3 (2001) CD001217
43. Hirsh J. Heparin. N Engl J Med 324 (1991) 1565-1574
44. Samama M.M., and Gerotziafas G.T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 109 (2003) 1-11
45. Dinwoodey D.L., and Ansell J.E. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin 26 (2008) 145-155
46. Bauer K.A. New anticoagulants. Curr Opin Hematol 15 (2008) 509-515
47. Clarke-Pearson D.L., Synan I.S., Hinshaw W.M., Coleman R.E., and Creasman W.T. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 63 (1984) 92-98
48. Martino M.A., Borges E., Williamson E., et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 107 (2006) 666-671
49. Clarke-Pearson D.L., Coleman R.E., Synan I.S., Hinshaw W., and Creasman W.T. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 145 (1983) 606-613
50. Clarke-Pearson D.L., DeLong E.R., Synan I.S., and Creasman W.T. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol 64 (1984) 689-694
51. Borstad E., Urdal K., Handeland G., and Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 67 (1988) 99-103
52. Fricker J.P., Vergnes Y., Schach R., et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 18 (1988) 561-567
53. Clarke-Pearson D.L., DeLong E., Synan I.S., Soper J.T., Creasman W.T., and Coleman R.E. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 75 (1990) 684-689
54. Kaaja R., Lehtovirta P., Venesmaa P., et al. Comparison of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol 47 (1992) 141-145
55. Clarke-Pearson D.L., Synan I.S., Dodge R., Soper J.T., Berchuck A., and Coleman R.E. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 168 (1993) 1146-1153
56. Maxwell G.L., Synan I., Dodge R., Carroll B., and Clarke-Pearson D.L. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 98 (2001) 989-995
57. Baykal C., Al A., Demirtaş E., and Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol 22 (2001) 127-130
58. von Tempelhoff G.F., Harenberg J., Niemann F., Hommel G., Kirkpatrick C.J., and Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16 (2000) 815-824
59. Collins R., Scrimgeour A., Yusuf S., and Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318 (1988) 1162-1173
60. Douketis J.D., Eikelboom J.W., Quinlan D.J., Willan A.R., and Crowther M.A. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 162 (2002) 1465-1471
61. Liebman H.A. Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control 12 Suppl. (2005) 11-16
62. Ahmad S., Jeske W.P., Walenga J.M., et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 5 (1999) 259-266
63. Agnelli G., Bergqvist D., Cohen A.T., Gallus A.S., Gent M., and PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 (2005) 1212-1220
64. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
65. Rasmussen M.S., Jorgensen L.N., Wille-Jørgensen P., et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4 (2006) 2384-2390
66. Orr J.W., Kelly F.J., and Roland P.Y. Perioperative care. In: Gershenson D.M., McGuire W.P., Gore M., Quinn M.A., and Thomas G. (Eds). Gynecologic cancer. Controversies in management (2004), Elsevier, Philadelphia, PA 631-648 [chapter 48]
67. Clarke-Pearson D.L. Prevention of venous thromboembolism in gynecologic surgery patients. Curr Opin Obstet Gynecol 5 (1993) 73-79
68. Adib T., Belli A., McCall J., et al. The use of inferior vena caval filters prior to major surgery in women with gynaecological cancer. BJOG 115 (2008) 902-907
69. Boyd M.E. Postoperative gynecologic infections. Can J Surg 30 (1987) 7-9
70. Mittendorf R., Aronson M.P., Berry R.E., et al. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. Am J Obstet Gynecol 169 (1993) 1119-1124
71. Tanos V., and Rojansky N. Prophylactic antibiotics in abdominal hysterectomy. J Am Coll Surg 179 (1994) 593-600
72. Stumpf P.G. Practical solutions to improve safety in the obstetrics/gynecology office setting and in the operating room. Obstet Gynecol Clin North Am 35 (2008) 19-35
73. McDonald P.J., and O'Loughlin J.A. Prophylactic antibiotics and prevention of surgical sepsis. Baillieres Clin Obstet Gynaecol 7 (1993) 219-236
74. Persson E., Bergström M., Larsson P.G., et al. Infections after hysterectomy. A prospective nation-wide Swedish study. The Study Group on Infectious Diseases in Obstetrics and Gynecology within the Swedish Society of Obstetrics and Gynecology. Acta Obstet Gynecol Scand 75 (1996) 757-761
75. Mikamo H., Kawazoe K., Izumi K., Watanabe K., Ueno K., and Tamaya T. Studies on the pathogenicity of anaerobes, especially Prevotella bivia, in a rat pyometra model. Infect Dis Obstet Gynecol 6 (1998) 61-65
76. Kobamatsu Y., Yamamoto R., Kaneuchi M., et al. Comparison of the results of radical hysterectomy: sequential observations in each period. Jpn J Clin Oncol 32 (2002) 103-107
77. Plonczynski D.J. Wise use of perioperative antibiotics. AORN J 81 (2005) 1260, 1264-8, 1271-2
78. Hansen C.T., Møller C., Daugbjerg S., et al. Establishment of a national Danish hysterectomy database: preliminary report on the first 13,425 hysterectomies. Acta Obstet Gynecol Scand 87 (2008) 546-557
79. Committee on Gynecologic Practice. Prophylactic use of antibiotics with abdominal hysterectomy. ACOG Comm Opin. Int J Gyn Obstet 1991;36:137.
80. Hemsell D.L., Johnson E.R., Hemsell P.G., Nobles B.J., and Heard M.C. Cefazolin for hysterectomy prophylaxis. Obstet Gynecol 76 (1990) 603-606
81. van Lindert A.C., Giltaij A.R., Derksen M.D., Alsbach G.P., Rozenberg-Arska M., and Verhoef J. Single-dose prophylaxis with broad-spectrum penicillins (piperacillin and mezlocillin) in gynecologic oncological surgery, with observation on serum and tissue concentrations. Eur J Obstet Gynecol Reprod Biol 36 (1990) 137-145
82. de Lalla F., Scalambrino S., Tassi P.G., et al. Piperacillin versus cefotetan as single-dose prophylaxis in abdominal hysterectomy: a prospective, randomized, multicenter study. J Chemother 5 (1993) 113-118
83. Janknegt R., Schepers J.P., Haest J.W., Fabius G.T., Lohman J.J., and Smeets A.P. Antimicrobial prophylaxis in hysterectomies: a double-blind, randomized, comparative study of a single dose of piperacillin (2 g) versus a single dose of amoxicillin-clavulanic acid (2.2 g). Infection 21 (1993) 214-219
84. Hemsell D.L., Johnson E.R., Hemsell P.G., Nobles B.J., Little B.B., and Heard M.C. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. Clin Infect Dis 20 (1995) 677-684
85. Cormio G., Di Fazio F., Cacciapuoti C., Bettocchi S., Borraccino L., and Selvaggi L. Prospective randomized study comparing amoxicillin-clavulanic acid with cefazolin as antimicrobial prophylaxis in laparotomic gynecologic surgery. Acta Obstet Gynecol Scand 82 (2003) 1130-1134
86. Anonymous. Use prophylactic antibiotics appropriately. Institute for Healthcare Improvement. Available at: http://www.ihi.org/IHI/Topics/PatientSafety/SurgicalSiteInfections/Changes/SSI+Use+Prophylactic+Antibiotics+Appropriately.htm. Accessed November 3, 2007.
87. Sevin B.U., Ramos R., Lichtinger M., Girtanner R.E., and Averette H.E. Antibiotic prevention of infections complicating radical abdominal hysterectomy. Obstet Gynecol 64 (1984) 539-545
88. Sevin B.U., Ramos R., Gerhardt R.T., Guerra L., Hilsenbeck S., and Averette H.E. Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol 77 (1991) 729-734
89. Bouma J., and Dankert J. Infection after radical abdominal hysterectomy and pelvic lymphadenectomy: prevention of infection with a two-dose peri-operative antibiotic prophylaxis. Int J Gynecol Cancer 3 (1993) 94-102
90. Orr Jr. J.W., Sisson P.F., Patsner B., et al. Single-dose antibiotic prophylaxis for patients undergoing extended pelvic surgery for gynecologic malignancy. Am J Obstet Gynecol 162 (1990) 718-721
91. Song F., and Glenny A.M. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials. Br J Surg 85 (1998) 1232-1241
92. Arnaud J.P., Bellissant E., Boissel P., et al. Single-dose amoxycillin-clavulanic acid vs. cefotetan for prophylaxis in elective colorectal surgery: a multicentre, prospective, randomized study. J Hosp Infect 22 (1992) 23-32
93. Kwok S.P., Lau W.Y., Leung K.L., Ku K.W., Ho W.S., and Li A.K. Amoxycillin and clavulanic acid versus cefotaxime and metronidazole as antibiotic prophylaxis in elective colorectal resectional surgery. Chemotherapy 39 (1993) 135-139
94. Dellinger E.P., Gross P.A., Barrett T.L., et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis 18 (1994) 422-427
95. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 56 (1999) 1839-1888
96. Bratzler D.W., and Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189 (2005) 395-404
97. Bratzler D.W., Houck P.M., Richards C., et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 140 (2005) 174-182
98. Bellantone R., Pacelli F., Sofo L., et al. Systemic perioperative prophylaxis in elective oncological colorectal surgery: cefotetan versus clindamicin plus aztreonam. Drugs Exp Clin Res 14 (1988) 763-766
99. Periti P., Mazzei T., and Tonelli F. Single dose cefotetan vs. multiple-dose cefoxitin-antimicrobial prophylaxis in colorectal surgery: results of a prospective multicenter, randomized study. Dis Colon Rectum 32 (1989) 121-127
100. Morton A.L., Taylor E.W., Lindsay G., and Wells G.R. A multicenter study to compare cefotetan alone with cefotetan and metronidazole as prophylaxis against infection in elective colorectal operations. Surg Gynecol Obstet 169 (1989) 41-45
101. Hershman M.J., Swift R.I., Reilly D.T., et al. Prospective comparative study of cefotetan with piperacillin for prophylaxis against infection in elective colorectal surgery. J R Coll Surg Edinb 35 (1990) 29-32
102. Skipper D., and Karran S.J. A randomized prospective study to compare cefotetan with cefuroxime plus metronidazole as prophylaxis in elective colorectal surgery. J Hosp Infect 21 (1992) 73-77
103. Periti P., Tonelli F., Mazzei T., and Ficari F. Antimicrobial chemoimmunoprophylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study. J Chemother 5 (1993) 37-42
104. Milsom J.W., Smith D.L., Corman M.L., Howerton R.A., Yellin A.E., and Luke D.R. Double-blind comparison of single dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Am J Surg 176 Suppl. 6A (1998) 46S-52S
105. Jagelman D.G., Fabian T.C., Nichols R.L., Stone H.H., Wilson S.E., and Zellner S.R. Single-dose cefotetan versus multiple-dose cefoxitin as prophylaxis in colorectal surgery. Am J Surg 155 (1988) 71-76
106. Fujita S., Saito N., Yamada T., et al. Randomized, multicenter trial of antibiotic prophylaxis in elective colorectal surgery: single dose vs. 3 doses of a second-generation cephalosporin without metronidazole and oral antibiotics. Arch Surg 142 (2007) 657-661
107. Palmer B.V., Mannur K.R., and Ross W.B. An observer blind trial of co-amoxiclav versus cefuroxime plus metronidazole in the prevention of postoperative wound infection after general surgery. J Hosp Infect 26 (1994) 287-292
108. Tonelli F., Mazzei T., Novelli A., Mazzoni P., Ficari F., and Italian Cooperative Group. Amoxicillin/clavulanic acid versus cefotaxime for antimicrobial prophylaxis in abdominal surgery: a randomized trial. J Chemother 14 (2002) 366-372
109. Mosimann F., Cornu P., and N'Ziya Z. Amoxycillin/clavulanic acid prophylaxis in elective colorectal surgery: a prospective randomized trial. J Hosp Infect 37 (1997) 55-64
110. Lewis R.T. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg 45 (2002) 173-180
111. Espin-Basany E., Sanchez-Garcia J.L., Lopez-Cano M., et al. Prospective, randomised study on antibiotic prophylaxis in colorectal surgery. Is it really necessary to use oral antibiotics?. Int J Colorectal Dis 20 (2005) 542-546
112. Kobayashi M., Mohri Y., Tonouchi H., et al. Randomized clinical trial comparing intravenous antimicrobial prophylaxis alone with oral and intravenous antimicrobial prophylaxis for the prevention of a surgical site infection in colorectal cancer surgery. Surg Today 37 (2007) 383-388
113. Goldstein E.J., Citron D.M., Vreni Merriam C., Warren Y., and Tyrrell K.L. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 44 (2000) 2389-2394
114. Shah P.M., and Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 52 (2003) 538-542
115. Yellin A.E., Hassett J.M., Fernandez A., et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents 20 (2002) 165-173
116. Solomkin J.S., Yellin A.E., Rotstein O.D., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237 (2003) 235-245
117. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., and Jarvis W.R. Guideline for prevention of surgical site infection. Am J Infect Control 27 (1999) 97-132
118. Itani K.M., Wilson S.E., Awad S.S., Jensen E.H., Finn T.S., and Abramson M.A. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 355 (2006) 2640-2651
119. Itani K.M., Jensen E.H., Finn T.S., Tomassini J.E., and Abramson M.A. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) 9 (2008) 131-137
120. Sexton D.J. Carbapenems for surgical prophylaxis?. N Engl J Med 355 (2006) 2693-2695
121. Koss K., Clark M.A., Sanders D.S., Morton D., Keighley M.R., and Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 8 (2006) 149-154
122. Vergidis P.I., and Falagas M.E. New antibiotic agents for bloodstream infections. Int J Antimicrob Agents 32 Suppl. 1 (2008) S60-S65 [Epub ahead of print]
123. Guaschino S., De Santo D., and De Seta F. New perspectives in antibiotic prophylaxis for obstetric and gynaecological surgery. J Hosp Infect 50 (2002) S13-S16
124. Keighley M.R. A clinical and physiological evaluation of bowel preparation for elective colorectal surgery. World J Surg 6 (1982) 464-470
125. Ambrose N.S., and Keighley M.R. Physiological consequences of orthograde lavage bowel preparation for elective colorectal surgery: a review. J R Soc Med 76 (1983) 767-771
126. Barker P., Trotter T., and Hanning C. A study of the effect of Picolax on body weight, cardiovascular variables and haemoglobin concentration. Ann R Coll Surg Engl 74 (1992) 318-319
127. Wolters U., Keller H.W., Sorgatz S., Raab A., and Pichlmaier H. Prospective randomized study of preoperative bowel cleansing for patients undergoing colorectal surgery. Br J Surg 81 (1994) 598-600
128. Gründel K., Schwenk W., Böhm B., and Müller J.M. Improvements in mechanical bowel preparation for elective colorectal surgery. Dis Colon Rectum 40 (1997) 1348-1352
129. Zmora O., Mahajna A., Bar-Zakai B., Hershko D., Shabtai M., Krausz M.M., and Ayalon A. Is mechanical bowel preparation mandatory for left-sided colonic anastomosis? Results of a prospective randomized trial. Tech Coloproctol 10 (2006) 131-135
130. Brownson P., Jenkins S.A., Nott D., and Ellenbogen S. Mechanical bowel preparation before colorectal surgery: results of a prospective randomized trial. Br J Surg 79 (1992) 461-462
131. Burke P., Mealy K., Gillen P., Joyce W., Traynor O., and Hyland J. Requirement for bowel preparation in colorectal surgery. Br J Surg 81 (1994) 907-910
132. Santos Jr. J.C., Batista J., Sirimarco M.T., Guimarães A.S., and Levy C.E. Prospective randomized trial of mechanical bowel preparation in patients undergoing elective colorectal surgery. Br J Surg 81 (1994) 1673-1676
133. Miettinen R.P., Laitinen S.T., Mäkelä J.T., and Pääkkönen M.E. Bowel preparation with oral polyethylene glycol electrolyte solution vs. no preparation in elective open colorectal surgery: prospective, randomized study. Dis Colon Rectum 43 (2000) 669-675
134. Fillmann L.S., Perondi F., Fillmann H.S., and Fillmann E.E.P. The elective resection for colo-rectal cancer without mechanical bowel preparation. Rev Bras Coloproctol 21 (2001) 246-248
135. Zmora O., Mahajna A., Bar-Zakai B., et al. Colon and rectal surgery without mechanical bowel preparation: a randomized prospective trial. Ann Surg 237 (2003) 363-367
136. Fa-Si-Oen PR, Buitenweg JA, van Geldere D, et al. The effect of preoperative bowel preparation with polyethylene glycol on surgical outcome in elective open colorectal surgery-a randomised multicenter trial. Abstract presented to the Fourth Belgian Surgical Week, Ostende; 2003.
137. Slim K., Vicaut E., Panis Y., and Chipponi J. Meta-analysis of randomized clinical trials of colorectal surgery with or without mechanical bowel preparation. Br J Surg 91 (2004) 1125-1130
138. Guenaga K.F., Matos D., Castro A.A., Atallah A.N., and Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev 2 (2003) CD001544
139. Guenaga K.F., Matos D., Castro A.A., Atallah A.N., and Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev 1 (2005) CD001544
140. van Geldere D., Fa-Si-Oen P., Noach L.A., Rietra P.J., Peterse J.L., and Boom R.P. Complications after colorectal surgery without mechanical bowel preparation. J Am Coll Surg 194 (2002) 40-47
141. Schein M., Assalia A., Eldar S., and Wittmann D.H. Is mechanical bowel preparation necessary before primary colonic anastomosis? An experimental study. Dis Colon Rectum 38 (1995) 749-752
142. Buckmire M., Parquet G., Seeburger J.L., Fukuchi S.G., and Rolandelli R.H. Effect of bowel preparation and a fiber-free liquid diet on expression of transforming growth factor and procollagen in colonic tissue preoperatively and postoperatively. Dis Colon Rectum 41 (1998) 1273-1280
143. Okada M., Bothin C., Kanazawa K., and Midtvedt T. Experimental study of the influence of intestinal flora on the healing of intestinal anastomoses. Br J Surg 86 (1999) 961-965
144. Rock J.A., and Thompson J.D. Te Linde's operative gynecology. 8th ed. (1996), Lippincott-Raven, Philadelphia
145. Charoenkwan K., Phillipson G., and Vutyavanich T. Early versus delayed (traditional) oral fluids and food for reducing complications after major abdominal gynaecologic surgery. Cochrane Database Syst Rev 4 (2007) CD004508
146. Rothnie N.G., Harper R.A., and Catchpole B.N. Early postoperative gastrointestinal activity. Lancet 2 (1963) 64-67
147. Watkins D.T., and Robertson C.L. Water-soluble radiocontrast material in the treatment of postoperative ileus. Am J Obstet Gynecol 152 (1985) 450-455
148. Pearl M.L., Valea F.A., Fischer M., and Chalas E. A randomized controlled trial of postoperative nasogastric tube decompression in gynecologic oncologic patients undergoing intra-abdominal surgery. Obstet Gynecol 88 (1996) 399-402
149. Cutillo G., Maneschi F., Franchi M., Giannice R., Scambia G., and Benedetti-Panici P. Early feeding compared with nasogastric decompression after major oncologic gynecologic surgery: a randomized study. Obstet Gynecol 93 (1999) 41-45
150. Steed H.L., Capstick V., Flood C., Schepansky A., Schulz J., and Mayes D.C. A randomized controlled trial of early versus "traditional" postoperative oral intake after major abdominal gynecologic surgery. Am J Obstet Gynecol 186 (2002) 861-865
151. Chase D.M., Lopez S., Nguyen C., Pugmire G.A., and Monk B.J. A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?. Am J Obstet Gynecol 199 (2008) 541.e1-541.e7 [Epub ahead of print]